Dose ranging safety and efficacy studies to advance novel mechanism-of-action small molecule leads to treat obesity-linked type 2 diabetes

Project: Other project

StatusFinished
Effective start/end date9/1/188/31/19

Funding

  • Ridgeline Therapeutics LLC: $82,973.00